J&J Innovative Medicine Infectious Diseases & Vaccines
在场
J&J Innovative Medicine Infectious Diseases & Vaccines 的所有者是 Johnson & Johnson.
是其中之一......
- Forbes Global 2000 (#45);
- Fortune 500 (#42);
- Global Fortune 500 (#115);
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Johnson & Johnson 是一家在股票代码 JNJ (US) 下上市的公司。
Johnson & Johnson 在 23 个国家有直接业务。Johnson & Johnson 拥有 65家子公司，其中包括 Abiomed、Ambrx 和 DePuy Synthes。
他们在：
涉及Johnson & Johnson的并购和融资。
- Johnson & Johnson 已收购 V-Wave (公布2024十月9号).
- Johnson & Johnson has announced the acquisition of Proteologix (公布2024六月21号).
- Johnson & Johnson has announced the acquisition of Proteologix (公布2024五月20号).
- Johnson & Johnson has announced the acquisition of Shockwave Medical (公布2024四月6号).
- Johnson & Johnson 已收购 Ambrx (公布2024一月11号).
- 查看更多"Johnson & Johnson"相关新闻 Hide news involving Johnson & Johnson
高管
查看带有其 3 名主要高管的组织结构图
J&J Innovative Medicine Infectious Diseases & Vaccines 搜索最多的简介
- Penny Heaton, Global Therapeutic Area Head
- Toon Overstijns, Global Commercial Strategy Leader
- Samuele Butera, President, US Pulmonary Hypertension and Retina
高管在Johnson & Johnson变化
- Scott Davis, Director, 正在办理退休 (新闻发布的2024九月11号).
- Kristen Mulholland 曾任 Head of Human Resources, Global Total Rewards, 将于 202410月1 升职为 Chief Human Resources Officer (新闻发布的2024八月26号).
- Peter Fasolo, Executive Vice President and Chief Human Resources Officer, 将于 202410月1 退休 (新闻发布的2024八月26号).
创建提醒
跟踪 J&J Innovative Medicine Infectious Diseases & Vaccines 的高管变动
生物技术
Johnson & Johnson 拥有 2,332 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- March Biosciences 刚刚宣布为 28 筹款数百万美元。 (公布2024十二月3号).
- Lyell Immunopharma 已收购 ImmPACT Bio (公布2024十一月29号).
- Hopo Therapeutics 刚刚宣布为 226 筹款数百万美元。 (公布2024十一月29号).
生物技术 行业的其他推荐联系人
消息
J&J Innovative Medicine Infectious Diseases & Vaccines 的最新新闻稿
- Media contacts
- Newsroom
- Blogs
- Johnson & Johnson Releases its 2022 Health for Humanity Report and We All Belong: 2022 DEI Impact Review
- Johnson & Johnson Named a 2023 Fortune World’s Most Admired Company and Ranked #1 on the Pharmaceutical Industry List
- Centre d'actualités >
- Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis | Janssen
- Janssen Reports Switching to SYMTUZA™ Results in Maintained High Virologic Suppression and No Resistance Development up to 96-Weeks in Virologically Suppressed Adults with HIV-1 | Janssen
- Home | Janssen
- View more press releases Close
通过电子邮件
